Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Albena Patroneva"'
Autor:
Albena Patroneva, Amee Revana, Vanessa Perez Patel, Daniel G. Glaze, Elizabeth Merikle, Krystle Davis
Publikováno v:
J Clin Sleep Med
STUDY OBJECTIVES: Excessive daytime sleepiness is common in Prader-Willi syndrome (PWS), with prevalence ranging from 52% to 100%. The goal of this study was to establish the content validity (ie, evidence that an instrument measures an intended conc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6722526c219357bcb29760912400707d
https://pubmed.ncbi.nlm.nih.gov/34437052
https://pubmed.ncbi.nlm.nih.gov/34437052
Publikováno v:
Sleep. 43:A291-A291
Introduction Pitolisant Expanded Access Clinical Evaluation (PEACE) provided adult patients with narcolepsy access to treatment with pitolisant while it was an investigational medication in the United States. Methods Pitolisant was titrated to 35.6 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e97c79a3358782195b68f0f1083087a
https://doi.org/10.1093/sleep/zsaa056.762
https://doi.org/10.1093/sleep/zsaa056.762
Publikováno v:
Sleep. 43:A283-A283
Introduction Cardiovascular diseases are comorbid in patients with narcolepsy. Cardiovascular adverse effects are of concern with narcolepsy medications because of this comorbidity and most patients require lifelong pharmacotherapy. Pitolisant, a sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21e1ba789cc2c882dde09cc613e7d490
https://doi.org/10.1093/sleep/zsaa056.740
https://doi.org/10.1093/sleep/zsaa056.740
Publikováno v:
Sleep. 42:A243-A243
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a378dfe7e4f380ce34eb9834faa3d841
https://doi.org/10.1093/sleep/zsz067.609
https://doi.org/10.1093/sleep/zsz067.609
Publikováno v:
Sleep. 42:A236-A236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caed16cf47d0208549f972a2512f007c
https://doi.org/10.1093/sleep/zsz067.590
https://doi.org/10.1093/sleep/zsz067.590
Autor:
Jean-Charles Schwartz, Philippe Robert, Craig W. Davis, Karl Doghramji, Catherine Scart-Grès, Albena Patroneva, Stephen P Wanaski, Andrew D. Krystal
Publikováno v:
Sleep. 42:A245-A245
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb662f78059bdabc169133fbe94fbb48
https://doi.org/10.1093/sleep/zsz067.613
https://doi.org/10.1093/sleep/zsz067.613
Autor:
Kasia Lobello, Sheldon H. Preskorn, Philip T. Ninan, Albena Patroneva, Jeffrey Paul, Christine J. Guico-Pabia, Qin Jiang, Alice I. Nichols
Publikováno v:
The Journal of Clinical Psychiatry. 71:1482-1487
Introduction Venlafaxine, a serotonin-norepinephrine reuptake inhibitor antidepressant, is metabolized primarily by the cytochrome P450 2D6 enzyme into O-desmethylvenlafaxine (ODV). The ODV/venlafaxine ratio can be used to distinguish between extensi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c960bb5d17946305abb9008d88668911
https://doi.org/10.4088/jcp.08m04773blu
https://doi.org/10.4088/jcp.08m04773blu
Autor:
Heather Silman, Jennifer A. Isler, Albena Patroneva, Michael E. Burczynski, Qin Jiang, Sheldon H. Preskorn, Alice I. Nichols, Saeeduddin Ahmed, Jeffrey Paul
Publikováno v:
Journal of Clinical Psychopharmacology. 29:39-43
Background: The goal of this study was to evaluate the impact of cytochrome P450 2D6 extensive metabolizer (EM) or poor metabolizer (PM) status on the pharmacokinetics of single doses of venlafaxine extended release (ER) and desvenlafaxine (administe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8959157bd7d168c61444ebbd4e527972
https://doi.org/10.1097/jcp.0b013e318192e4c1
https://doi.org/10.1097/jcp.0b013e318192e4c1
Autor:
Eileen C Helzner, Sheldon H. Preskorn, Christine J Guico-Pabia, Jeffrey Paul, Alice I. Nichols, Albena Patroneva
Publikováno v:
Journal of Psychiatric Practice. 14:368-378
BACKGROUND The cytochrome P450 2D6 (CYP2D6) enzyme is responsible for metabolizing approximately 25% of pharmaceutical agents. Individuals with impaired CYP2D6 metabolism and those concomitantly receiving agents that inhibit CYP2D6 can have variation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f6af9b013c493005114d19dd4603ab3
https://doi.org/10.1097/01.pra.0000341891.43501.6b
https://doi.org/10.1097/01.pra.0000341891.43501.6b